SCHEMBL5624141

SCHEMBL5624141

O=C(O)N(c1ccccc1-c1ccccc1)S(=O)(=O)Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
BCAT2 O15382 1/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
PTGS2 P35354 1/20 0.37
TACR1 P25103 1/20 0.37
FABP3 P05413 1/20 0.37
FABP4 P15090 1/20 0.37
FABP5 Q01469 1/20 0.37
ALDH1A1 P00352 3/20 0.36
STAT3 P40763 1/20 0.36
HNF4A P41235 1/20 0.36
ESR1 P03372 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9474853 0.89 PTGER1 (0.42) MEN1KMT2ASMN1; SMN2ESR1
SCHEMBL7086352 0.83 HNF4A (0.40) MEN1KMT2ASMN1; SMN2BCAT2CHRNB2
SCHEMBL9175530 0.75 C5AR1 (0.50) KMT2ASMN1; SMN2PTGS2STAT3ESR1
SCHEMBL23374991 0.74 KMT2A (0.46) MEN1KMT2ASMN1; SMN2BCAT2CHRNB2
SCHEMBL4748576 0.74 KMT2A (0.44) KMT2ASMN1; SMN2ALDH1A1ESR1HPGD
SCHEMBL9452056 0.73 ALDH1A1 (0.36) ALDH1A1CA2
SCHEMBL27637324 0.71 BCAT2 (0.47) MEN1KMT2ASMN1; SMN2BCAT2CHRNB2
SCHEMBL5883327 0.71 TACR1 (0.54) MEN1KMT2ASMN1; SMN2BCAT2TACR1
SCHEMBL7200742 0.69 MEN1 (0.46) MEN1KMT2ASMN1; SMN2BCAT2TACR1
SCHEMBL10785562 0.69 NPSR1 (0.48) MEN1KMT2ASMN1; SMN2BCAT2CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7244845-B2 Process for preparing cyclic N-substituted alpha-imino carboxylic acids SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-07-17 US claimed
US-20050131231-A1 Process for preparing cyclic N-substituted alpha-imino carboxlic acids AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-06-16 US claimed
US-7244845-B2 Process for preparing cyclic N-substituted alpha-imino carboxylic acids SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-07-17 US disclosed
US-20050131231-A1 Process for preparing cyclic N-substituted alpha-imino carboxlic acids AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131231-A1 Process for preparing cyclic N-substituted alpha-imino carboxlic acids MMP1, MMP2, MMP9 MEN1 1522/4885KMT2A 3325/4885SMN1; SMN2 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.